HLA-C* 06: 02 genotype is a predictive biomarker of biologic treatment response in psoriasis
N Dand, M Duckworth, D Baudry, A Russell… - Journal of Allergy and …, 2019 - Elsevier
Background Biologic therapies can be highly effective for the treatment of severe psoriasis,
but response for individual patients can vary according to drug. Predictive biomarkers to
guide treatment selection could improve patient outcomes and treatment cost-effectiveness.
Objective We sought to test whether HLA-C* 06: 02, the primary genetic susceptibility allele
for psoriasis, predisposes patients to respond differently to the 2 most commonly prescribed
biologics for psoriasis: adalimumab (anti–TNF-α) and ustekinumab (anti–IL-12/23). Methods …
but response for individual patients can vary according to drug. Predictive biomarkers to
guide treatment selection could improve patient outcomes and treatment cost-effectiveness.
Objective We sought to test whether HLA-C* 06: 02, the primary genetic susceptibility allele
for psoriasis, predisposes patients to respond differently to the 2 most commonly prescribed
biologics for psoriasis: adalimumab (anti–TNF-α) and ustekinumab (anti–IL-12/23). Methods …
